Vaccination is an effective strategy in the prophylaxis of influenza [7] and [8]. Previous pandemic influenza vaccine development initiatives focused on the influenza A/H5N1 subtype [9]. An A/H5N1 influenza vaccine, containing the AS03 adjuvant system (an

α-tocopherol and squalene selleck compound based oil-in-water emulsion) [10], was highly immunogenic in children and adults [11], [12], [13] and [14]. At the time of the H1N1/2009 pandemic, the World Health Organization (WHO) recommended the development of plain and adjuvanted pandemic vaccines [15] and [16]. Based on previous experience, an AS03-adjuvanted influenza candidate vaccine with 3.75 μg or 1.9 μg hemagglutinin (HA) was developed against the novel swine-origin H1N1/2009 pandemic influenza strain, which elicited immune responses that met US and European regulatory immunogenicity criteria in children and adults [17], [18], [19],

[20], [21], [22] and [23]. The current trial assessed the safety and immunogenicity of two antigen-sparing formulations and three dosing regimens of a vaccine composed of A/California/7/2009 (H1N1)v-like split virus antigen adjuvanted with AS03, in children from 10 to <18 years of age. This phase II, parallel group, randomized, observer-blind, multi-center study (NCT01035749) enrolled children 10–17 years of age across five centers in Slovakia and one center in Estonia. The study was conducted in accordance PCI-32765 supplier with the Good Clinical Practice guidelines, the Declaration of Helsinki and local regulations. All study-related documents were approved by an Institutional Review Board. Written informed consent was obtained from the parents of all children prior to conducting any study-related procedures. Written informed assent was obtained according tuclazepam to country guidance. A summary of the study protocol is available at www.gsk-clinicalstudyregister.com (Study ID 113883). Healthy children were randomized (3:3:3:5) to receive either one dose of 3.75 μg HA AS03A-adjuvanted vaccine (0.5 mL), or one or two doses of 1.9 μg HA AS03B-adjuvanted

vaccine (0.25 mL per dose), or one dose of 15 μg HA non-adjuvanted pandemic vaccine (0.5 mL; as an active comparator). For children receiving a single dose primary vaccination, a saline placebo (0.5 mL) was given at Day 21 instead of a second vaccine dose. All children received a booster dose of the same vaccines at Day 182. Treatments were allocated by GSK’s central randomization system on Internet (SBIR, GlaxoSmithKline Vaccines, Wavre), using a minimization algorithm accounting for center and history of seasonal influenza vaccination with equal weight. The children, their parents, and study personnel evaluating study end points were unaware of the vaccine administered. Study personnel involved in the preparation and administration of the study vaccines were not involved in evaluation of study endpoints.